PrasugrEl moNotherapy after DrUg eLUting stent deployMent as a Management Of patients who are uNsuitable for lOng-term dual antiplatelet therapy
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2019
Price : $35 *
At a glance
- Drugs Prasugrel (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Acronyms PENDULUM
- 07 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 10 Jan 2018 Status changed from not yet recruiting to recruiting.
- 04 Jul 2017 New trial record